Annexon offers a high-risk, asymmetric biotechnology opportunity: validated GBS efficacy and a pivotal GA readout could support a $19.00 base or $56.25 bull-case 2031 share price.
Overview
Annexon is a pre-commercial biotechnology company developing targeted immunotherapies against C1q, the initiating molecule in the classical complement cascade. It has no approved products and generated $0.0 million of revenue in Q2 2026, but its two late-stage assets address large medical gaps. Tanruprubart produced strong Phase 3 GBS data in 241 patients, including a 2.4-fold week-8 GBS-DS improvement, 31 fewer median days to independent walking, and 28 fewer median days on mechanical ventilation versus placebo. The EU MAA is under review and a U.S. BLA is targeted for Q4 2026. Vonaprument reduced the risk of ≥15-letter BCVA loss by 72% in Phase 2 ARCHER; ARCHER II’s Month 15 readout is expected in Q4 2026. **The principal investment case is a clinical and regulatory inflection point rather than current earnings.** Q2 net loss was $55.3 million, cash and investments were $209.2 million, and an Oxford facility of up to $200.0 million extends runway into 2028. Consensus forecasts sales of $38.92 million in 2027 and $257.12 million in 2028, with $64.5 million of 2028 net income. At $3.94, consensus analysts target $15.29 over 12 months, while the report’s probability-weighted 2031 value is $24.71. Near-term catalysts are the BLA, ARCHER II, and ANX1502 data.